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Summary 
In studies of antigenic peptide presentation, we have found a healthy volunteer whose lymphoblastoid 
cells were unable to present three different virus-derived epitopes to cytotoxic T  lymphocytes 
(CTL) despite expressing the correct restricting HLA-B27 molecules on the cell surface. B cell 
lines were established from other members of the donor's family, including individuals suffering 
from ankylosing spondylitis and related diseases,  and were tested for their ability to function 
as target cells in the same assay. None of the eight B cell lines that expressed HLA-B27 presented 
a known peptide epitope to CTL. However, cells from a family member that expressed HLA-B8 
could present an epitope peptide restricted by that molecule. The B27 molecule in this family 
proved to be the B2702 subtype on isoelectric focusing gels, appearing in exactly the same position 
as B2702 from other cell lines that did present the peptide. To exclude mutations resulting in 
noncharged amino acid substitutions, cDNA coding for B2702 was doned from the proband's 
cell line and sequenced. No coding changes were found. The cloned cDNA was transfected into 
HLA-A- and B-negative HMy/C1R cells, and the B2702 molecules generated in this environment 
rendered these cells, after incubation with peptide, susceptible to lysis by peptide-specific CTL. 
These data are compatible with the presence of a factor(s),  possibly HLA linked, interfering 
with antigen presentation by otherwise normal B2702 molecules in this family. 
H 
LA class I molecules, comprised of a polymorphic heavy 
chain and an invariant molecule, fl2-microglobulin, are 
present on almost all nucleated cells.  The function of these 
molecules is to present peptide antigens to CTL (1-4). After 
translation and translocation into the endoplasmic reticulum, 
the  heavy  chains  form  trimolecular  complexes  with  /32- 
microglobulin and those peptides that are able to bind speci- 
fically (5-7).  These complexes are transported through the 
Golgi apparatus to the cell surface. Here they can be recog- 
nized, if they contain foreign peptides, by the antigen receptors 
of specific CTL. 
Although numerous studies have indicated that any cell 
line expressing an HLA class I molecule should be able to 
present peptide epitopes restricted by that allele to the ap- 
propriate CTL (3, 4, 8, 9), recently some exceptions to this 
rule have been found. Mutant cell lines were generated in 
vitro that,  although synthesizing normal amounts of class 
I heavy chains, fail to form the trimolecular complexes with 
/32-microglobulin and endogenously derived peptides. Sur- 
face expression could be restored if the cells were incubated 
with peptides known to be epitopes (10,  11). Although the 
defects in these cell lines have not been fully elucidated, at 
least one of the genes involved is located within the MHC 
(11) and may be a peptide transporter (12).  The possibility 
that MHC-linked genes affect antigen processing was raised 
by Livingstone et al. (13), who identified a rat strain in which 
a gene in the MHC class II region modified the function of 
a rat class I molecule, altering its recognition by alloreactive 
T  cells  and  interfering  with  its  ability  to  present  minor 
histocompatibility antigens to CTL. Again, the ATP-binding 
cassette transporter gene family members that map in this 
region are candidates (14-17).  Cell lines have also been de- 
scribed that were unable to present peptides known to be 
specific for the HLA class II molecules on their surface (18); 
these cell lines may lack some of the enzymes that trim the 
peptides to the right size to fit into the peptide binding groove 
(18). All of these findings imply that there are genetic factors, 
some of which map to the MHC,  that are able to modify 
antigen presentation. 
Here we describe cells from a healthy human donor that 
were unable to present peptide epitopes to CTL via HLA- 
B27, despite expressing normal amounts of this molecule on 
the cell surface. This phenotype was not caused by a muta- 
tion of the HLA molecule itself,  and cells  from all HLA- 
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same behavior. These findings may be explained by the pres- 
ence of a gene or genes linked to the MHC complex. The 
implications for HLA and disease associations are discussed. 
Materials and Methods 
Propagation of CTL  Lines.  HLA-B27-restricted influenza A 
nucleoprotein peptide-specific CTL lines were grown as previously 
described (9).  Briefly, PBMC, at 2  x  l@/ml,  taken from two 
donors, HF (HLA-A2, -A3, -B7, -B2705) and GR (HLA-A3, -A31, 
-B2705),  were incubated with influenza A  virus X31  (titer 103 
hemagglutination units) at a dilution of 10 -3, for 1 h at 37~  in 
the absence of serum and then in RPMI 1640 with 10% FCS for 
7 d at 37~ 
CTL lines were grown from this bulk culture by mixing the 
T cells with equal numbers of autologous B-lymphoblastoid cells 
(BCL  1) that  had been incubated for a period of 1 h  with  the 
influenza A nucleoprotein peptide 380-393 (synthesized byJ. Roth- 
bard, Immunologic, Palo Alto, CA) at 50 #g/ml, and then irradi- 
ated at 3,000 tad. These lines were grown in medium supplemented 
with 10 U/ml rib2 (Cetus Corp., Emeryville, CA). Each line was 
shown to be specific only for the stimulating peptide presented 
by HLA-B27 before being used in these experiments. An HLA-B8- 
restricted CTL line was grown on the nucleoprotein (NP) peptide 
379-402,  which is an epitope presented by HLA-B8 (Sutton et al., 
manuscript in preparation); this was  also highly specific. 
The method used to generate HLA-B27-restricted HIV gag- 
specific CTL lines has been fully described (19). Briefly, lympho- 
cytes from a B27 HIV-seropositive donor were stimulated with 
1-d-old autologous PHA (Wellcome Diagnostics, Greenville, NC) 
-activated lymphocytes. After 7 d, cells were restimulated with ir- 
radiated autologous BCL preincubated with gag peptide 265-279 
at  50  #M.  T  cell  growth  factor (Lymphocuh T;  Biotest AG, 
Dreieich, Germany) at 10 U/ml was added to the culture. EBV-spec- 
ific CTL lines were generated exactly as described previously (20). 
Cytotoxicity Assay.  Effector cells were harvested and tested for 
their ability to lyse S1Cr-labeled target calls in a 4-h assay. Effectors 
and  targets  were mixed together in  wells  of a  96-well  round- 
bottomed plate in 150 #1 of KPMI 1640/10% FCS. 50 #1 of pep- 
tide at various dilutions was added to appropriate wells. Control 
wells had either medium or Triton X-100 in place of effector cells 
added to estimate spontaneous and maximal 51Cr release. After a 
4-h incubation, 20 #1 of supernatant was harvested from each well 
onto a filtermat, dried, scintillant  fluid added and the radioactivity 
measured in a Beta-plate counter (LKB Instruments, Inc., Gaithers- 
burg, MD). The results are expressed as percent specific lysis and 
calculated as follows: percent specific lysis =  100x  (experimental 
counts -  spontaneous release)/(detergent control -  spontaneous 
release). 
In most of the experiments, three control cell lines were used: 
LY is an EBV-transformed  B lymphocyte cell line expressing  the 
HLA-B2702 molecule. It was established from a healthy donor and 
made available to us by Dr. A. Rickinson (University of Birming- 
ham). P815-B2702  is a mouse mastocytoma cell line transfected 
with the HLA-B2702 molecule, kindly donated by Dr. E. Weiss 
(University of Munich). HMy/CIR-B2702 cells transfected with 
the same molecule were a gift from Dr. J. Lopez de Castro (Funda- 
cion Jimenez Diaz, Madrid, Spain). C1K cells, which are identical 
1Abbreviations used in  this paper: BCL,  B-lymphoblastoid cells; NP, 
nudeoprotein. 
to HMy/CIK cells, were given to us by Dr. J. Frelinger (Univer- 
sity of North Carolina) and used for the transfection experiments. 
Flow Cytornetry.  10  s cells were stained with 1:50 to 1:500 di- 
lutions of the anti-HLA-B27 mAb ME1  (21) for 30 min.  After 
washing the cells in PBS-0.1% BSA, FITC-labeled rabbit anti-mouse 
Ig antibody (Sigma Chemical Co., St. Louis, MO) was added to 
a dilution of 1:100 for 20 min on ice, followed by another wash 
in PBS-0.1%  BSA. Finally, the cells were resuspended in 0.5 ml 
PBS containing 1% FCS and 1% formaldehyde. 5,000 cells were 
counted on a Facscan  |  flow cytometer (Becton Dickinson & Co., 
Mountain View,  CA) using Consort 30 software. 
Pulse Chase Labeling.  10  s cells in log phase  of growth were 
spun down and resuspended in 2 ml methionine-free RPMI 1640 
with 5% FCS and incubated at 37~  in a small flask for 40 min. 
3sS-Methionine  (ICN,  Irvine,  CA),  0.5  mCi,  was  then added. 
After 15 rain, labeling was stopped by the addition of 300-#1 ali- 
quots to either 20 ml ice-cold  PBS (0 time point sample)  or to 
5 ml RPMI with 10% FCS and 2 mM cold methionine at 37~ 
(other time points). These were removed from the incubator at 
the intervals shown and immediately added to 20 ml ice-cold PBS. 
The cells in PBS were centrifuged at 4~  and the pellet lysed in 
I ml lysis buffer (0.5% NP-40, 20 mM Tris, pH 8, 10 mM EDTA, 
pH 8, 0.1 M NaC1, 1 mM PMSF). After 30 rain on ice, the nuclei 
were sedimented at 14,000 rpm for 5 min at 4~  The lysates were 
stored on ice until all samples were ready for preclearing. Lysates 
were precleared with 150 #110% Pansorbin (Calbiochem Corp., San 
Diego, CA) for I h, centrifuged, and the supernatant was divided 
into two equal aliquots for immunoprecipitation with 3 #1 HC10 
(22) or W6/32 (23) ascites. These aliquots were incubated with 
antibody for 1 h at 4~  then 100 #1 10% protein A-Sepharose 
(Sigma Chemical Co.) in lysis buffer was added and samples mixed 
end over end for 30 min at 4~  Protein A-Sepharose beads were 
then washed at 4~  twice with 20 mM "Iris, pH 8, 10 mM EDTA, 
pH 8, 0.1 M NaC1, 0.5% NP-40, 0.1% SDS, 1% BSA, once with 
10% lysis buffer in 0.5 M  NaC1,  and once in lysis buffer.  They 
were then resuspended in 60 #1 sample buffer (9.5 M urea, 2% 
NP-40, 2% ampholines,  pH 3.5-10, 5% 2-ME) and incubated at 
room temperature for 30 rain. The beads were sedimented by spin- 
ning briefly in a microcentrifuge, and 40 #1 of the supernatant was 
removed for analysis on isoelectric  focusing gel. 
lsoelectric Focusing.  One-dimensional IEF was  performed ac- 
cording to the method of Neefjes et al. (24) in 4.5% polyacryl- 
amide gels  containing monoacrylamide/bisacrylamide (Bio-Rad 
Laboratories,  Richmond, CA) (ratio 30:1.6),  9 M urea, 2% NP- 
40, 4% ampholyte pHS-7 (LKB Instruments, Inc.),  and 1% am- 
pholyte pH 3.5-10 (LKB Instruments Inc.). To polymerize 30 ml 
gel solution, 60/~1 freshly prepared 10% (wt/vol) ammonium per- 
sulphate,  and 30 #1 TEMED were used. 16-cm gel plates were run 
on a Protean II apparatus (Bio-Rad Laboratories).  The upper buffer 
was 50 mM NaOH, and the lower buffer 20 mM H3PO4. A con- 
stant voltage of 880 V was set, with the current limited to 12 mA 
per gel and power to 8 W, allowing the maximum voltage to be 
achieved over several hours. The run was continued for 13-16 h, 
the gels fixed in 10%  acetic acid for 30 min,  then treated with 
Amplify for 30 min, dried, and exposed to Kodak XAK film. The 
position of bands corresponding to individual HLA class I alleles 
was determined by comparison with cell lines of known HLA type 
and published information (22,  24,  25). 
DNA Cloning and Sequencing,  Total cellular RNA was isolated 
from 10  s cells by a single-step  method (26).  First-strand cDNA 
was synthesized using the Red Module kit (Invitrogen Corpora- 
tion, San Diego, CA) according to the manufacturer's instructions. 
cDNA coding for B locus HLA class I products was amplified using 
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CTC CCC AGA CGC CGA 3' for the 5' untranslated region, and 
5' CCG CAA GCT TCT GGG GAG GAA ACA CAG GTC AGC 
GGA AC 3' for the 3' untranslated region. Standard PCR buffer 
was used (27) with the Mg  2§  concentration at 1.5 mM. After 3 
min at 94~  initial denaturation,  the samples were amplified for 
25 cycles of I  min at 94~  1 min at 67~  and 1.5 min at 72~ 
in a temperature cycler (Grant Instruments, Cambridge, UK). The 
1.3-kb amplified product was purified on SeaPlaque  (FMC Bio- 
products,  Rockland,  ME)  low  melting point  agarose gel.  The 
amplified band was excised from the gel, melted and cut sequen- 
tially with HindlII and SalI (Promega Biotec, Madison, WI). After 
another purification step on low melting point agarose, the band 
was excised and mixed at a ratio of 3:1 with M13mp19, which was 
previously cut with the same enzymes and then gel purified. The 
melted gel mixture was kept at 37~  T4 ligase buffer and ligase 
(Promega Biotec) were added, and the ligation was carried out at 
room temperature for 5 h. The gel was remelted and 10/zl of the 
gel was mixed with 10/A water. Escherichia coliJMlOg-competent 
cells were transformed according to the manufacturers instructions 
(Promega Biotec).  White  plaques were picked,  grown,  and  se- 
quenced using T7 polymerase and Deaza GTP sequencing mixes 
(Pharmacia  Fine  Chemicals,  Piscataway,  NJ).  The  sequencing 
primers used were published previously (28). 
cDNA Expression.  The eukaryotic expression vector pKG5 (29) 
was a gift from Dr. Pita Braddock (Imperial Cancer Research Fund, 
Institute of Molecular Medicine, Oxford, UK). The HLA-B2702 
cDNA grown in M13mp19 was subcloned using the purification 
of DNA fragments in SeaPlaque agarose gels according to the pro- 
tocol described above. E. coli  HB 1061-competent cells were trans- 
formed, grown with standard methods (27). The plasmid was iso- 
lated using a scaled-up version of the protocol described by He et 
al. (30). After KNAse digestion (KNAce; Stratagene,  La Jolla, CA) 
and ethanol precipitation the DNA was cut with ScaI (Promega 
Biotec). The precipitated DNA was dissolved at 1,000 #g/ml in 
water, and 107 C1R cells were mixed with 50 #l DNA and elec- 
troporated using a GenePulser (Bio-Rad Laboratories) set to 230 
V and 250 #F. Cells were resuspended in 25 ml RPMI containing 
10%  FCS and antibiotics and plated into 24-well  plates (Costar, 
Cambridge, MA). After 2 d, selective medium containing 1.8 mg/ml 
G418 (Sigma Chemical Co.) was added. 4 wk later, cells from the 
wells containing living cells were stained with the mAb ME 1. 
The cells from individual wells expressing the highest amounts of 
B27  were expanded and used as targets in CTL assays. 
Results 
Inability  to Present Peptide Epitopes  via  HLA  B27.  The 
influenza virus NP peptide 380-393  is an epitope presented 
by HLA-B2705 and recognized by the CDS-positive peptide- 
specific HLA-B27-restricted cytotoxic T cell lines HF and GR. 
As we have previously shown, all B2705-positive cell lines 
tested presented this peptide. Several NP 380-393-specific sub- 
lines of the HF and GR CTL were generated from different 
donations of peripheral blood; some were able to recognize 
this peptide when it was presented by the cell lines expressing 
another B27 subtype, B2702,  which differs from B27005  at 
three amino acid residues at positions 77,  80,  and 81 (31). 
As shown in Fig. 1, the HLA-B2702-positive lymphoblastoid 
cells LY and transfectant cell lines P815-B2702 and HMy/C1R- 
B2702,  both expressing the HLA-B2702 gene, were able to 
present this peptide to an HF CTL line.  However, neither 
BCL nor PHA-activated T  cell blasts  from B2702-positive 
donor NW presented this peptide. Shorter and longer pep- 
tides based on the same region of the NP (9) were also tested 
but  none was recognized (data not shown). 
Similar results were obtained with CTL specific for the 
HIV virus gag peptide 265-279  also restricted by HLA-B27. 
Again, NW cells invariably failed to present the added pep- 
tide, while in the same experiments the HMy/CIR-B2702 
and P815-B2702  cells presented this peptide (Fig.  2). 
The BCL NW expressed HLA-B8 as well as -B2702 and 
was tested for its ability to present an HLA-B8-restricted pep- 
tide, NP 379-402,  to highly specific CTL. As shown in Fig. 
3, this peptide was presented efficiently to the BS-restricted 
CTL, which indicates that in this cell line there is no gener- 
alized defect in peptide presentation to CTL. 
HLA-B2702 Restricted EBV-specific CTL from LY Fail to Lyse 
NW BCL.  It was not possible to generate influenza-specific 
CTL from HLAoB2702-positive donors LY and NW. How- 
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Figure  1.  Peptide NP 380-393 
presentation by HLA-B2705- and 
B2702-positive  cell lines to an HLA- 
B27-restricted peptide-specific  CTL 
line HF at an E/T ratio of 4:1. (A) 
The B2705 autologous BCL (O) 
and  the  B2702-transfected P815- 
B2702 cells (A) and HMy/C1R- 
B2702 cells (1"7) could present the 
peptide to the effector cells while 
the B2702-positive NW cell line 
(11) did not. (B) The same peptide 
tested with  peptide-specific B27- 
restricted CTL line from donor GR 
at an E/T ratio of 6:1 lysing  peptide- 
treated autologous  cells (O), B2702- 
positive LY BCL (V']), and B2702- 
transfected P815-B2702 cells (A), 
but not recognizing B2702-positive 
NW BCL (11) or NW PHA blasts 
(O). 
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Figure 2.  Failure  of NW cells to present the HIV gag peptide 265-276. 
Peptide-specific B27-restricted CTL were  derived from a HLA-B2705- 
positive, HIV-1 seropositive donor 007. NW B2702 BCL (I)  did not 
present the peptide, but B2705-positive HF BCL (0) and transfectants 
HMy/CIR-B2705 (O) and HMy/C1R-B2702  (D) did. 
were generated  from donor LY. All of the four CTL lines 
lysed the autologous LY cells~ but not NW BCL. This con- 
trasted with the ability of three of the CTL lines to lyse B2705- 
positive SC cells. This result supports the observations made 
with the influenza NP and HIV gag-specific CTL from HLA- 
B2705-positive donors, that B2702 and 82705 molecules can 
present the same peptides, but again, NW cells failed to present 
the expected  epitope  (Fig.  4). 
The Nonpresenting Phenotype Is Inherited.  We established 
EBV-transformed BCL from relatives of the donor NW. As 
shown in the family tree (Fig.  5), the cell lines came from 
three generations.  Several family members were B27 positive 
and three have had some form of HLA-B27-associated  dis- 
ease. The nine B27-positive cell lines were tested as targets 
80- 
60 
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Figure 4.  LY CTL lines specific for EBV presented by HLA-B27 could 
distinguish between autologous target cells (Ira) and NW BCL (I). Three 
out of four lines (LY-1, LY-2, and LY-3) reacted with HLA-B2705-positive 
SC BCL (IN), while none recognized B2702-positive  NW BCL (I) and 
the HLA-mismatched  BCL [B (~). 
with HLA-B27-restricted  peptideIspecific  CTL lines, using 
the influenza A NP peptide 380-393; all failed to present this 
peptide epitope (Table 1). Cells from six family members were 
also tested with the HLA-B27-restricted  HIV gag peptide 
265-279.  The CTL line used recognized LY cells  and the 
HMy/C1R-B2702 transfectants treated with the gag 265-279 
peptide,  but did not kill peptideitreated  cells from B2702- 
positive family members (Table 1). Furthermore, when pre- 
sentation of antigen by cells infected with influenza virus was 
tested, autologous and LY cells presented the epitope derived 
from virus while BCL from a family member did not (Fig. 6). 
Expression of HLA-B2702 by NW and LY BCL.  When 
B cell lines from NW and family members  were tested for 
surface expression of HLA-B27 with the ME1 mAb, it was 
found that they expressed similar amounts orB27 molecules 
to the B2702 cell line LY, which could present the peptides 
(Fig.  7). 
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Figure 3.  Peptide presentation by HLA-B8 is intact in NW BCL. An 
influenza NP 380-393-specific  HLA-B8 (but not B27)  -restricted CTL 
line recognized the autologous CM BCL (O) and NW BCL (~l) equally 
well in the presence of peptide at 20/xM; neither CM BCL (X) nor NW 
BCL (A) was killed in the absence of peptide. Killer/target  (K/T) ratios 
were as shown. 
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I  6 
[]  o 
A/ET 
8 
A/F  A/G  I 
o  [] 
G/H  A/H 
￿9  Iritis 
￿9  Ankylosing Spondylitis 
[]  Sacroiliitis 
The family W, HLA class  I haplotypes of the individuals  studied 
are given on the left. Three individuals have had AS or related disorders, 
as indicated. The proband, NW, is member 8. 
364  Modulated Antigen Presentation by HLA-B27 Table  1.  Failure of BCL from Members of Family NW to Present NP 380-393 to Specific CTL 
Targets* 
Exp.  B2705r  B2702s  8(NW)  1  2  3  4  5  6  7  10 
1 NP  II  361  20  4  2  9  10 
2 NP  II  30  15  0  0  0  0  0  0  0 
3 gag  II  34  16  7  3  0  0  6  0 
* Family members  are designated by their numbers as given in Fig. 5. 
HLA-B2705-matched  target  cells were  HMy/CIR in Exp.  1, autologous  (GR) in Exp.  2,  and HH BCL  in Exp.  3. 
S HLA-B2702-matched  target  cells were  HMy/CIR in Exps.  1 and 2,  and LY BCL in Exp.  3. 
II Peptide NP 380-393 was  tested at concentrations between 1.0 and 50/~M; results  at  10 #M are shown. 
Results are shown as percent  specific lysis. CTL were HF CTL in Exp.  1, GR CTL in Exp.  2, and 007 CTL in Exp.  3.  All three lines were 
previously shown to be highly specific for the pepdde and restricted by HLA-B27.  Killer target  ratios were  10:1, 9:1,  and 10:1 in Exps.  1, 2, and 
3,  respectively. 
To examine the assembly and glycosylation of HLA class 
I molecules in NW compared with LY cells, BCL from each 
donor were pulse labeled with 35S-methionine, chased with 
cold methionine, and HLA class I molecules were immuno- 
precipitated at intervals thereafter.  By using the mAbs HC10 
and W6/32, specific for unfolded and folded heavy chains, 
respectively (22), it was possible to follow assembly and sia- 
lation in IEF gels, which dearly distinguishes between different 
class I types (21, 23, 24, 31-33). As shown in Fig. 8, HLA- 
B2702  associated  with  /32-microglobulin  more  rapidly in 
NW cells compared with LY cells, but subsequent sialation 
occurred at about the same rate. Folding of B27 was markedly 
slower than HLA-A24 and -B35  in the LY cells and faster 
than HLA-B8 in the NW cells. 
The NW HLA-B2702 Molecule Is Structurally Normal.  Side 
by side comparison in IEF gels,  which can distinguish six 
HLA-B27 subtypes (32), indicated that B2702 from LY and 
NW ran in the same position. To exclude mutations resulting 
60 
50 
m  40 
m 
>,  30 
o  ~  20 
10 
0  ~ 
Target  +  0  +  NP  peptide  +  AX31  'flu  virus 
Figure 6.  Failure to present epitope peptides generated during viral in- 
fection. (Left) Untreated cells; (middle) cells sensitized with peptide; and 
(right) the same cells after viral infection, showing similar patterns of lysis. 
The killer CTL were an HF peptide 380-393 B27-restricted line used at 
a K/T  ratio  of 5:1. Target  cells were  B2705-positive HF BCL  (U), 
HMy/C1R-B2702  (11), B2702-positive LY BCL (11), and family member 
10 (see Fig. 5) (~). 
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in noncharged amino acid substitutions, cDNA coding for 
the B2702  molecule was cloned from the NW BCL.  Se- 
quencing of the 1.3-kb insert revealed two noncoding differ- 
ences from the published B2702 DNA sequence  (31). One 
was in the oe3 domain at position 708 and the other was lo- 
cated in the 3' untranslated region at position 1067. Neither 
would result in changes in the amino acid sequence. 
The B2702 from  the Cell Line NW  Presents Peptide in a 
Different Cellular Environment.  The cloned cDNA used for 
the sequencing was subcloned into the expression vector pKG5 
and transfected into CIK cells. As shown in Fig. 8,  these 
cells expressed  amounts of B2702  molecules on the surface 
that were comparable with those on BCL. The transfectant 
cell line was lysed by the HF influenza-specific CTL line in 
the presence  of the influenza NP peptide 380-393  (Fig.  9). 
2E~3  ~  CIR-A2 
1 
CIR-B2702  cDNA  _o  1 
E  I  .I "t  / 
I  l'  !  , /  N.W. 
c  4i  !1  hill  ';"ii  :~::/:~ 
o  l,  (  I  ~  LY.  !i  li !.  i~::: : 
.>  I  t  L  t ~ 
-!~ L~  !E! 1  !~  !~2 
Fluorescense  intensity 
Figure 7.  Histograms  after  staining  the cell  lines  with the B27-specific 
monoclonaI  antibody  ME1. The four cell lines tested  are indicated:  C1R- 
A2 (HMy/CIR  cells  transfected  with HLA-A2),  HMy/CIR-B2702  cDNA 
(HMy/CIR  ceils transfected  with B2702 cDNA prepared  from  NW BCL), 
NW BCL, and LY BCL. Figure 8.  Processing  of  HLA class I molecules  in NW 
BCL and LY BCL. The two cell lines were pulse labeled 
with 3ss methionine and then chased with cold methio- 
nine for the times shown (0-240 rain). Labeled  class I mol- 
ecules were immunoprecipitated with antibodies HC10 
(h), specific  for free heavy chain, and W6/32 (w) specific 
for flz-microglobulin-assodated  heavy chain. Precipitates 
were run on two isoelectric  focusing slab gels and the au- 
toradiographs (NW and LY) are shown, with basic pH 
at the top. The positions of each of the class I molecules 
agrees with previously  published results (21, 23, 24, 31, 
32), except for the band marked B35", which probably 
represents a B35 variant molecule, and ?C, which prob- 
ably  represents  a C locus  product. Immunoprecipitates  were 
not treated with neuraminidase  and the emergence  of the 




>,  30 
2010  ~  ................. 
0  !  .....  =  |  !  0  1  10  50 
(NP)  micromolar  NP  380-393 
Figure 9.  Presentation of peptide by HLA-B2702 from NW was re- 
stored by transfection into HMy/C1R cells. GR CTL peptide, NP 380- 
393 specific and HLA-B27 restricted, were tested at a K/T ratio of 6:1 
with peptide treated (at the concentrations shown) autologous GR BCL 
(O), B2702-positive  LY BCL (I-1), NW BCL (Q),  B2702 transfectant 
P815-B2702 (A), HMy/CIR transfected  with B2702 from NW (A), and 
a control of HMy/CtR transfected with HLA B3S (I). 
Discussion 
Here we describe several EBV-transformed B cell lines from 
members of a  family,  in which  two cases of radiologically 
confirmed ankylosing spondylitis have occurred and a third 
individual has had an episode of anterior uveitis.  In the ex- 
periments described here, all B27-positive B cell lines from 
this family failed to present two peptide epitopes via the HLA- 
B2702 molecule, irrespective of whether the peptides were 
added exogenously or generated during viral infection. In con- 
trast,  the unrelated BCL LY and two transfectant cell lines, 
all expressing the same B2702 restriction element, were able 
to present  the peptides  and  the  virus.  An  effect caused by 
transformation by EBV was unlikely because, although PHA 
blasts can readily present peptides to CTL (2), peptide-treated 
NW  PHA blasts  were not lysed.  Conversely,  HLA-B2702 
expressed in both the EBV-negative mouse cell line P815 and 
the EBV-positive HMy/C1R line could present antigen. When 
EBV was tested as an antigen,  it was found that four CTL 
lines recognizing EBV presented by B2702 could distinguish 
between the BCL of NW  and LY. When the B2702 mole- 
cule was cloned from one family member and expressed in 
HLA-A- and -B-negative HMy/CIR cells, these transfectants 
could present  the  peptide  epitope. 
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peptides were from HLA-B2705 donors and were primed with 
this B27 subtype in vivo. HLA-B2702 differs from B2705 
at three amino acids: aspartic acid replaced by asparagine at 
position  77, threonine by isoleucine at 80, and leucine by 
alanine at 81. All three side chains point into the peptide 
binding groove of HLA-B27, but are sited at one of its ends. 
It is clear from these results that B2702 can bind the two 
peptides used in these experiments and that each can be rec- 
ognized by some of the CTL clones that normally respond 
to peptide presented by HLA-B2705. Three of the four CTL 
lines specific  for EBV from the B2702-positive donor LY rec- 
ognized EBVotransformed B2705-positive cells, supporting 
the idea that there is an overlap in the peptides presented by 
these two closely related HLA molecules. Because HLA-B8- 
positive cells from NW presented a peptide epitope via this 
restriction element, a general defect in these cell lines, for 
example, the lack of accessory  molecules such as CD11a-CD18, 
was excluded. 
The prerequisite for recognition and killing of a target cell 
by CTL is the presence of a structurally intact MHC mole- 
cule on the target cell that is able to bind the viral peptides 
in the peptide binding groove and can interact with the TCR. 
Although unrelated peptides can bind to the same MHC mol- 
ecule with relatively low affinity (34, 35), epitope peptides 
bind with high affinity and the interaction  is very specific 
(6, 7, 36-38).  Since single amino acid substitutions  at cer- 
tain parts of the MHC molecule can abrogate recognition 
by CTL by interfering with either peptide binding or inter- 
action with the TCR (8, 39, 40), it was important to show 
that the B2702 molecule on the cell lines from the studied 
family did not have any additional changes in the amino acid 
sequence. This was excluded by sequencing of cDNA cloned 
from the proband,  NW;  the derived amino acid sequence 
showed no coding changes from that published  for HLA- 
B2702 (31). 
There is considerable current interest in the series of events 
that leads to the intracellular formation of the heavy chain- 
~2-microglobulin-peptide complexes. This was stimulated by 
the identification of the mutant cell lines RMA-S (10), 721.174 
(11), and 721.134 (12), which show defects in this assembly 
process. These cells produce normal amounts of structurally 
intact MHC heavy chain and B2-microglobulin molecules 
but their assembly is impaired and they express very few stable 
class I molecules on the cell surface. Peptide-specific CTL fail 
to recognize internally derived antigen when these cells are 
infected with influenza virus but do lyse cells when they have 
been incubated in the epitope peptide (10, 11). These results 
imply that the peptide induces MHC class I molecule assembly 
or stabilizes assembled molecules on the cell surface (5, 10, 
11, 38, 41). The cell lines described here are different. They 
expressed normal amounts of HLA-B2702 molecules on the 
surface, and the expression did not increase after incubation 
in the presence of peptides (data not shown). Exogenously 
added peptides, as well as virus antigens, were not presented. 
Given the sequence identity of the B2702 in cells that did 
or did not present peptides, we reasoned that the cellular en- 
vironment must influence antigen presentation by this mole- 
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cule. To test this hypothesis we cloned the cDNA encoding 
the HLA-B2702 from the NW cell line and expressed it in 
the HLA-A- and -B-negative HMy/CIR cell line. In this cel- 
lular environment, the cloned B2702 molecule functioned 
differently, presenting the peptide. This implies the presence 
of one or more factors that influence peptide  presentation 
by this molecule in the original  host cell. BCL from nine 
individuals, representing three generations in the NW family, 
were established. All those with HLA-B2702 failed to present 
peptide to CTL lines that could recognize peptide presented 
by LY, HMy/C1R-B2702,  and P815-B2702. The occurrence 
of the described phenotype in every B27-positive member 
of this family can be explained by two mechanisms. It is pos- 
sible that the frequency of the gene or genes responsible for 
this effect is very high in the population,  in which case a 
recessive or dominant gene could account for the observa- 
tions. The other possibility is that the trait is dominant and 
is linked to the HLAoB2702 haplotype. 
The findings described here are reminiscent of those in a 
congenic rat strain in which a gene mapping to the MHC 
class II region modified antigen presentation  by the other- 
wise normal class I RT1.A  ~ molecules, rendering them un- 
recognizable  both for alloreactive  T cell clones and CTL specific 
for the HY antigen (13). The members of the ABC trans- 
porter superfamily, located in the class II region (14-17), are 
obvious candidate genes. Phenotypically,  the deficit in an- 
tigen presentation  by this rat allele shows some similarity 
to our findings. However, in the rat, the RT1.A  ' molecule 
was retained within the endoplasmic reticulum or cis-Golgi 
complex for an unusually long period in the PVG.R1 and 
R8 congenic lines, and rapid processing was dominant in F1 
cells (42). This differs in important detail from our prelimi- 
nary study of processing of HLA-B2702 in NW and LY cells; 
association between B2702 heavy chain  and B2-microglo- 
bulin,  measured by loss of reactivity with HC10 antibody 
and acquisition of the W6/32 epitope,  was delayed in LY 
cells compared with NW. The difference was not large but 
was definite and reproducible;  subsequent passage through 
the Golgi complex, measured by increasing negative charge 
of the B2702 band due to addition of sialic acid, occurred 
at a similar rate in both cell lines. The way antigenic peptides 
are generated and transported into the endoplasmic reticulum 
is far from understood. The faster assembly of the B2702 mol- 
ecules in  NW  could be due to  a more efficient peptide- 
generating or -transporting system. Another possibility is that 
the peptides reaching the endoplasmic reticulum in NW cells 
are different and some of them may have a very high affinity 
for the HLA-B2702 molecule. This could explain both faster 
assembly and the apparent inability of externally added pep- 
tides to bind to the B27 molecules in these cells. If the pheno- 
type is caused by a rare dominant gene (or genes) and the 
responsible element(s) is linked to the MHC, a possibility 
compatible with the presented findings, the ABC transporter 
genes mapping here will be candidates if they are found to 
be polymorphic. These possibilities are currently under detailed 
investigation. 
HLA-B27 is one of the most widely investigated human 
HLA class I molecules because of its strong association with ankylosing spondylitis, reactive arthritis, juvenile spondyloar- 
thropathy, psoriatic arthritis, and enteropathic arthropathy 
(43). More than 90% of Caucasian patients who suffer from 
ankylosing spondylitis carry the B27 allele, compared with 
7% of controls, making this the strongest known HLA dis- 
ease association (44).  However, the probability that a B27- 
positive individual will develop the disease depends on the 
family history. While in general only 2% of the HLA-B27- 
carrying population is affected,  if there is a family history 
of the disease the incidence may be as high 20% (45),  as il- 
lustrated by the occurrence of three cases in the family inves- 
tigated here.  These observations suggest that inherited ele- 
ments, other than the B27 molecule itself, play an important 
role in the pathophysiology. These need not necessarily be 
linked to the MHC although our observations may suggest 
that this is the case. The association of the unusual behavior 
of the NW B2702 molecule with the history of ankylosing 
spondylitis, and related disorders,  in this family argues that 
the nonpresenting phenotype might be associated with in- 
creased risk of developing the disease. If such a linkage can 
be demonstrated it will support the view that the peptide- 
presenting function of HLA-B2702 is important in the patho- 
genesis  of ankylosing spondylitis. 
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